TABLE 1.

Clinical characteristics of lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) patients with FANCD2 high or low expression based on TCGA database.

Clinical factors		LUAD			LUSC
		Low	High	p Value	Low	High	p Value
Age, n (%)	Median (IQR)	67 (59, 74)	64 (59, 72)	0.036	69 (63, 74)	67 (60, 73)	0.033
	≤65	115 (22.3%)	140 (27.1%)	0.043	87 (17.6%)	104 (21.1%)	0.170
	>65	142 (27.5%)	119 (23.1%)		158 (32%)	144 (29.2%)
Gender, n (%)	Female	158 (29.5%)	128 (23.9%)		79 (15.7%)	52 (10.4%)	0.008
	Male	109 (20.4%)	140 (26.2%)		172 (34.3%)	199 (39.6%)
Smoker, n (%)	No	47 (9%)	28 (5.4%)	0.018	8 (1.6%)	10 (2%)	0.797
	Yes	210 (40.3%)	236 (45.3%)		238 (48.6%)	234 (47.8%)
T stage, n (%)	T1	98 (18.4%)	77 (14.5%)	0.031	61 (12.2%)	53 (10.6%)	0.416
	T2	127 (23.9%)	162 (30.5%)		138 (27.5%)	156 (31.1%)
	T3	29 (5.5%)	20 (3.8%)		40 (8%)	31 (6.2%)
	T4	11 (2.1%)	8 (1.5%)		12 (2.4%)	11 (2.2%)
N stage, n (%)	N0	175 (33.7%)	173 (33.3%)	0.580	167 (33.7%)	153 (30.8%)	0.321
	N1	44 (8.5%)	51 (9.8%)		58 (11.7%)	73 (14.7%)
	N2	38 (7.3%)	36 (6.9%)		17 (3.4%)	23 (4.6%)
	N3	0 (0%)	2 (0.4%)		3 (0.6%)	2 (0.4%)
M stage, n (%)	M0	187 (48.4%)	174 (45.1%)	0.088	197 (47%)	215 (51.3%)	0.270
	M1	8 (2.1%)	17 (4.4%)		5 (1.2%)	2 (0.5%)
Pathologic stage, n (%)	Stage I	147 (27.9%)	147 (27.9%)	0.455	128 (25.7%)	117 (23.5%)	0.491
	Stage II	61 (11.6%)	62 (11.8%)		76 (15.3%)	86 (17.3%)
	Stage III	44 (8.3%)	40 (7.6%)		41 (8.2%)	43 (8.6%)
	Stage IV	9 (1.7%)	17 (3.2%)		5 (1%)	2 (0.4%)
OS event, n (%)	Alive	180 (33.6%)	163 (30.5%)	0.134	144 (28.7%)	142 (28.3%)	0.928
	Dead	87 (16.3%)	105 (19.6%)		107 (21.3%)	109 (21.7%)	0.777
DSS event, n (%)	Alive	198 (39.7%)	181 (36.3%)	0.079	183 (40.7%)	178 (39.6%)
	Dead	51 (10.2%)	69 (13.8%)		43 (9.6%)	46 (10.2%)
PFI event, n (%)	Alive	162 (30.3%)	147 (27.5%)		177 (35.3%)	177 (35.3%)	1.000
	Dead	105 (19.6%)	121 (22.6%)		74 (14.7%)	74 (14.7%)